To ask the Scottish Executive for what reason treatment with eculizumab for patients with paroxysmal nocturnal haeamoglobinuria is not funded in Scotland Scotland has robust, equitable and transparent arrangements for the introduction of newly licensed and cost-effective medicines to treat all conditions, including those to treat rare conditions, through the Scottish Medicines Consortium (SMC) and NHS Quality Improvement Scotland.